Introduction: Financial incentives for smoking cessation increase smoking abstinence and decrease Beck Depression Inventory (BDI) scores among depression-prone pregnant and postpartum women. The present study is a secondary analysis using the Brief Symptom Inventory (BSI) to examine whether this treatment impacts a broader array of mood and anxiety symptoms. Methods: Participants (N = 253) were pregnant cigarette smokers who participated in four controlled clinical trials examining the efficacy of financial incentives for smoking cessation. Women were assigned to an intervention wherein they earned vouchers exchangeable for retail items contingent on smoking abstinence (Contingent, n = 143) or a control condition wherein they received comparable vouchers independent of smoking status (Noncontingent, n = 110). Participants were categorized as depression-prone (n = 105) or depression-negative (n = 148) based on self-reported history of depression and BDI scores at intake. A prior study demonstrated that financial incentives decreased depressive symptoms among depression-prone women in this sample. The present study examined whether those effects extended to a broader array of mood and anxiety symptoms using the BSI. Effects of treatment, time, and depression status were examined using repeated measures analyses of covariance. Results: In addition to depressive symptoms, financial incentives reduced a multitude of BSI scores among depression-prone women, including the BSI global measure of distress and seven symptom subscales. Treatment effects were discernible by late pregnancy, peaked at 8 weeks postpartum, and dissipated by 24 weeks postpartum. Discussion: In addition to reducing smoking, this financial incentives treatment appears to reduce a range of mood and anxiety symptoms among depression-prone pregnant and postpartum women. Implications: This study adds evidence that providing financial incentives contingent on smoking cessation lowers a broad array of psychiatric symptoms, as measured by the BSI, among depression-prone pregnant and newly postpartum women during a time of heightened risk for peripartum mood disorders.
Introduction
In recent years, there has been a shift in peripartum health literature from focusing primarily on postpartum depression to examining a broader array of antepartum and postpartum mood and anxiety symptoms. As research has further progressed in the field of peripartum mental health, the characterization of peripartum mood and anxiety disorders has broadened from an initial focus on three main disorders (maternal blues, postpartum depression, and puerperal psychosis) to recognition that peripartum mood and anxiety disorders include a range of psychiatric and emotional impairments throughout pregnancy and the postpartum period (eg, symptoms of Obsessive-Compulsive Disorder, Anxiety, Panic Disorder, Bipolar I and II [1] [2] [3] [4] [5] ). Cigarette smoking, a behavior highly comorbid with psychological symptoms, has been found to exacerbate peripartum mood and anxiety symptoms in a dose-dependent manner. More specifically, women who smoke prior to becoming pregnant or in the antepartum period endorse higher levels of depressive and anxious symptomatology in the postpartum, with heavier smokers endorsing greater symptomatology. [6] [7] [8] [9] [10] This is not specific to the peripartum period, as symptom severity has been shown to vary by smoking status in samples of male and female adults with mood and anxiety disorders. [11] [12] [13] We know of no definitive pharmacological explanation for these relationships, although considerable ongoing research is examining changes in nicotine acetylcholine receptor regulation corresponding to the bidirectional relationship of nicotine use and mood and anxiety disorders. 14, 15 Furthermore, the reduced activation of the brain's reward system in response to natural reinforcers as well as reduced dopamine transporter availability are hypothesized to be related to persistent negative affect in smokers. 16 Genetic factors are thought be involved as well. 11, [16] [17] [18] [19] In terms of adverse impacts, smoking alone causes serious adverse birth outcomes (eg, preterm birth, low birth weight 20, 21 ). The combination of mood and anxiety symptoms and smoking may lead to additional increased complications for mother (eg, decreased quality of life) and baby (eg, poor birth outcomes, impaired development). 20, [22] [23] [24] The most tragic of these outcomes includes suicide, which accounts for approximately 20% of postpartum deaths and is the second most common cause of mortality among postpartum women in the United States. 22 Thus, a smoking cessation treatment that decreases mood and anxiety symptomatology is of considerable potential clinical importance.
Voucher-based financial incentives are a highly effective smoking cessation treatment for pregnant and newly postpartum women. 25 In this intervention, incentives in the form of vouchers exchangeable for retail items are delivered contingent on biochemically verified abstinence from smoking. Our research group recently reported that in conjunction with increasing smoking abstinence, this intervention significantly decreases depressive symptoms among depression-prone women. 26 That result is consistent with other research showing that financial incentives for abstinence from illicit-drug use decreases depressive symptoms among nonpregnant adults with substance use disorders. 27, 28 The inclusion of more mood and anxiety symptoms during both pregnancy and the postpartum in peripartum health literature, coupled with the unexpected finding by Lopez et al., 26 encouraged us to examine whether this intervention might impact a broader constellation of symptoms beyond those captured by the Beck Depression Inventory (BDI). More specifically, we assessed whether this incentives-based treatment reduces mood and anxiety symptoms measured by the Brief Symptom Inventory (BSI), a self-report questionnaire with a global measure of psychiatric distress and nine symptom subscales, which was completed by all women in our cessation trials. The BSI is commonly used in substance abuse studies and has sufficient breadth to capture the range of psychiatric symptoms in pregnant and newly postpartum cigarette smokers. [28] [29] [30] We also wanted to examine whether smoking status acted as a mediator of any treatment effects on mood and anxiety symptoms.
Methods

Participants
Participants were 253 pregnant cigarette smokers examined in the Lopez et al. 26 study, with 36 women excluded due to missing baseline BSI assessments. All participants were in one of four controlled clinical trials examining the efficacy of financial incentives for smoking cessation. [31] [32] [33] [34] The local institutional review board approved each trial and all women provided written informed consent. Women were recruited from obstetric practices and the Women, Infants, & Children (WIC) program in Burlington, Vermont and surrounding areas. If a woman endorsed smoking within the past 7 days at any of the participating clinics, she was invited to an intake assessment to further determine eligibility. Inclusion criteria included self-reported smoking at entry into prenatal care, residing within the study clinic's county with no plans to leave the area through 6 months postpartum, being at least 18 years of age, and English speaking. Exclusion criteria included incarceration, pregnancy beyond 25 weeks, previous participation in the study, or residing with a current participant.
Assessments
Participants attended a total of eight formal assessments. Antepartum assessments were completed at intake (<25 weeks gestational age), in early pregnancy (1 month following intake), and in late pregnancy (≥ 28 weeks gestational age). Postpartum assessments were conducted at 2, 4, 8, 12, and 24 weeks after delivery. During assessments, participants completed questionnaires examining sociodemographics, current smoking status/history, as well as the BDI (version 1A) 35 and BSI. 36 Self-reported smoking abstinence was biochemically verified using urinary cotinine enzyme immunoassay testing.
Treatment Conditions
After determining eligibility and completing the informed consent process, participants were randomly assigned to one of two conditions: an experimental condition that received abstinent-contingent incentives (Contingent) or a control condition that received incentives independent of smoking status (Noncontingent). These methods have been described previously in more detail. 33 In brief, those in the Contingent condition received vouchers for biochemically verified abstinence from smoking using breath carbon monoxide (CO) samples ≤ 6 ppm in the first week followed by urinary cotinine levels <80 ng/mL using onsite Enzyme Immunoassay Testing. Participants in the Noncontingent condition received vouchers equivalent to the average earnings anticipated for the Contingent condition. Vouchers were available from study initiation through 12 weeks postpartum. All participants received usual care for smoking cessation.
Psychological Vulnerability: Depression-Prone Classification
The BDI (version 1A) is a 21-item self-report questionnaire focused on depressive symptomatology. 35 Each item is ranked on a 4-point scale ranging from 0 to 3 on intensity of symptoms within the past week. Women who endorsed a history of depression or who met the threshold for moderate depression (BDI score ≥17) at intake were categorized as depression-prone. 35 Women who did not endorse a history of depression and had a BDI score below the clinical threshold were categorized as depression-negative.
Mood and Anxiety Symptomatology
The BSI is a 53-item self-report questionnaire with a measure of overall symptom severity (the Global Severity Index, GSI) and nine subscales: Somatization, Obsessive-Compulsive, Interpersonal Sensitivity, Depression, Anxiety, Hostility, Phobic Anxiety, Paranoid Ideation, and Psychoticism. 36 Each item is ranked on a 5-point scale ranging from 0 to 4 on intensity of symptoms within the past week. Raw scores are converted to standardized t scores using norms based on relevant populations (eg, non-patient, psychiatric outpatient, or psychiatric inpatient), with a t score ≥ 0.63 considered within clinical range. 36 Non-patient norms were used in this study. The BSI has strong internal consistency, with Cronbach's coefficient alpha for each subscale ranging from 0.71 to 0.85 and test-retest reliability ranging from 0.68 to 0.91. 37 Convergent validity of the BSI and its subscales, when comparing to the Minnesota Multiphasic Personality Inventory, the Wiggins content scales, and Tryon cluster scales, ranges from r = .30-.72. 37 
Statistical Methods
Baseline demographic and smoking characteristics were compared between treatment conditions (Contingent vs. Noncontingent) and between depression status groups (depression-prone vs. depression-negative) using chi-square and t tests. A secondary analysis of baseline characteristics was completed using two-way analysis of variance and logistic regression to examine the interaction between treatment and depression status. Baseline BSI subscale scores were analyzed using a two-way analysis of variance with treatment group, depression status, and the interaction of treatment condition and depression status in the model. BSI subscale scores were analyzed for effects of treatment condition, depression status, time (seven periodic assessments), and the interaction of those three factors using repeated measures analyses of covariance (ANCOVA) with the respective baseline subscale score as the covariate. The simple effects of treatment were examined within each depression status group at each of the seven time-points. Analysis of covariance with the baseline subscale score as a covariate was used to investigate the role of smoking status as a mediator of the effects of treatment on BSI subscale scores at 8 weeks postpartum (time of peak effects). Smoking status was defined as 7-day point prevalence abstinence (ie, biochemically verified, self-reported abstinence from smoking within the past week). All analyses were performed using SAS Version 9 statistical software (SAS Institute, Cary, NC). Missing data were handled using maximum likelihood estimation. Statistical significance was set at α < .05.
Results
Participant Characteristics
Participants were young (M = 24.0, SD = 5.0), socioeconomically disadvantaged women. The majority completed 12 or fewer years of education (83%), were unmarried (83%), without full-time employment (52%), and without private health insurance (81%; Table 1 ). Among the 253 participants, 143 women were randomized into the Contingent condition and 110 into the Noncontingent condition. No significant differences in baseline characteristics were observed 
Mood and Anxiety Symptoms
Depression-prone women endorsed significantly higher scores on all baseline BSI subscales compared to depression-negative women (p < .05). Within the depression-prone group, Contingent participants had significantly higher baseline BSI subscale scores compared to Noncontingent participants (p < .05), except for Somatization. Thus baseline scores were used as covariates in analyses. Figure 1A shows BSI Depression subscale scores among depressionprone and depression-negative women in both treatment conditions across assessments. Examining this subscale confirmed that the treatment effects on depressive symptoms observed using the BDI in Lopez et al. 26 were discernible on the BSI. There were significant main effects of treatment (F(1,1236) = 4.08, p < .05), depression status (F(1,1236) = 7.40, p = .01), and time (F(6,1233) = 9.60, p < .001), as well as a significant two-way interaction of depression status and time (F(6,1233) = 4.89, p < .001), and a three-way interaction of treatment, depression status, and time (F(6,1233) = 2.36, p < .05). By the late-pregnancy assessment, the depression-prone Contingent women had Depression subscale scores indistinguishable from the scores within depression-negative women, while the scores within the depression-prone Noncontingent women remained significantly elevated. These differences between depression-prone women peaked in the Contingent and Noncontingent conditions at 8 weeks postpartum and remained discernible through 12 weeks postpartum (the end of treatment; Figure 1A ). There was no evidence of treatment effects within the depression-negative women at any of the assessment time points. Figure 1B shows scores among depression-prone and depressionnegative women in both treatment conditions across assessments on the BSI's global measure of distress, the Global Severity Index (GSI). Examining the GSI represented the first step in assessing whether differences between treatment groups within the depression-prone women started at late pregnancy, peaked at 8 weeks postpartum, and continued through 12 weeks postpartum ( Figure 1B ). There was no evidence of treatment effects within the depression-negative women.
Treatment Effects on Depressive Symptoms
Treatment Effects on Global Distress Levels
Treatment Effects on Other Psychological Symptoms
In addition to significant treatment effects on the GSI and the Depression subscale, there were significant main effects of treatment or interactions of treatment with depression status and time across each of the remaining BSI subscales (p < .05), except Hostility. Those effects were specific to the depression-prone women and largely followed the same time-course as the GSI and the Depression subscale ( Table 2 ). At 8 weeks postpartum (time of peak effects), the depression-prone Contingent women had scores below the clinical threshold on the GSI and seven subscales while the Noncontingent women had scores above the threshold on the GSI and five subscales, with the remaining three subscales at or above the cut-point if standard error is considered. Figure 2 shows scores at 8 weeks postpartum within the depression-prone women across each of the BSI subscales to illustrate the magnitude and consistency of the observed treatment effects.
Possible Mediating Effects of Smoking Status on Treatment Effects Among Depression-Prone Women
Point prevalence smoking status at 8 weeks postpartum significantly predicted scores at this time-point only on the Interpersonal Sensitivity subscale (F(1,75) = 4.83, p < .05). As described above, there were significant treatment effects on each of the BSI subscales except Hostility at 8 weeks postpartum. When smoking status, treatment condition, and baseline BSI scores were considered in the model together, smoking status played a mediating role, as the treatment effect lost significance for the Depression and Interpersonal Sensitivity subscales among depression-prone women (F(1,74) = 3.76, p > .05; (F(1,74) = 3.58, p > .05, respectively). Significance levels of treatment effects on the GSI, Somatization, Anxiety, Phobic Anxiety, and Psychoticism subscales were also reduced, although remained significant, when smoking status was included in the models.
Discussion
The present study examined the impact of a financial incentives smoking cessation intervention on mood and anxiety symptomatology as an extension of Lopez et al., 26 which demonstrated that this treatment decreased depressive symptoms in depression-prone women. The current study demonstrates that those treatment effects extend across a range of mood and anxiety symptoms consistent with current models of peripartum mood disorders. [1] [2] [3] [4] [5] Regarding time-course, these findings are consistent with results from other studies demonstrating that, among at-risk women, mood and anxiety symptoms often begin in the antepartum and continue into the postpartum, with the highest risk period for peripartum mood disorders occurring between 6 to 8 weeks postpartum. [38] [39] [40] [41] [42] It is also worth noting that the observed treatment effects occurred despite the depression-prone Contingent condition having significantly higher baseline BSI subscale scores relative to the depression-prone Noncontingent condition. BSI subscale scores for the depression-prone Contingent women were virtually equivalent to those of the depression-prone Noncontingent women by the early pregnancy assessment and reduced to levels similar to the depression-negative women by the late pregnancy assessment. This significant reduction in symptoms in a subset of women with higher baseline scores further highlights this smoking cessation treatment's potential additional benefit of reducing mood and anxiety symptoms among depression-prone pregnant and newly postpartum women.
Changes in smoking status mediated treatment effects across two subscales (Depression and Interpersonal Sensitivity), and played a role in effects on the GSI and five subscales (Somatization, Anxiety, Phobic Anxiety, and Psychoticism) in the present study, supporting other research indicating that smoking status does impact psychological symptomatology. [11] [12] [13] [14] In addition to the influence of smoking status, other aspects of this treatment likely contribute to the reduction of mood and anxiety symptoms. For example, this intervention may impact symptoms by providing repeated opportunities to interact with meaningful environmental reinforcement contingencies.
With total earnings and number of visits matched, the contingency on receiving incentives is the only programmed difference between conditions. This incentives treatment may target hallmark depressive and anxious symptoms (ie, withdrawal from the environment and avoidance) 43 by making the consequences (ie, earning incentives or not) of behavior (ie, abstaining or continuing to smoke) more salient and thereby actively engaging participants with their environment. This opportunity to interact with environmental contingencies has similarities with Behavioral Activation, an effective treatment for depression that re-engages patients through increasing interactions with positive reinforcement. 44 The present study has several limitations that merit mention. First, diagnostic instruments were not used; therefore, it is unclear whether participants met formal criteria for any psychological disorder throughout the study. However, it is worth noting that the BSI has a clinical cut-point (t ≥ 0.63), 36 and at 8 weeks postpartum, scores decreased below that threshold in the depression-prone Contingent women on the GSI and seven subscales. Scores in the depression-prone Noncontingent group remained above that level on the GSI and five subscales. These differences were observed despite the depression-prone Contingent women having significantly higher baseline BSI subscale scores. Notably, the BSI was not specifically developed for pregnant women and may overpathologize normal processes that occur during the peripartum (eg, somatic complaints, anxiety related to the baby's well-being, baby blues). However, if this were the case, any over-representation should be observed equally between treatment conditions, with decreases in mood and anxiety symptoms matched throughout the study, which was clearly not represented here. Such limitations notwithstanding, these results offer further evidence suggesting that providing financial incentives contingent on smoking cessation lowers a broad array of mood and anxiety symptoms among depression-prone women during a time of heightened risk for peripartum mood disorders. 
